GI pharmaceutical company closes $60M fundraising round — 3 insights

Gastroenterology-focused pharmaceutical company Landos Biopharma closed a $60 million series B financing round.

What you should know:

1. RTW Investments and Perceptive Advisors co-led the fund, with Osage University Partners and entities affiliated with Paul Manning contributing.

2. The company will use the funds to support the development of its ulcerative colitis and Crohn's disease drug candidate, as well as additional pipeline candidates.

3. RTW Investments and Perceptive Advisors each appointed a person to Landos' board as a result of the investment.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast